From the Department of Plastic & Reconstructive Surgery, St George's Hospital, London.
Department of Plastic & Reconstructive Surgery, Stoke Mandeville Hospital, Aylesbury.
Ann Plast Surg. 2022 Sep 1;89(3):331-335. doi: 10.1097/SAP.0000000000003249. Epub 2022 Jun 11.
The mainstay of treatment for venous ulceration is conservative wound management and lifelong compression therapy. For patients with recalcitrant ulcers, free flap reconstruction has been proposed as a treatment option to reconstruct the diseased soft tissues as well as the underlying insufficient venous system. This review systematically evaluates the outcomes of free flap reconstruction for chronic venous ulcers in the lower limb.
A protocol was developed a priori and registered on the PROSPERO database. A systematic search of literature was performed in MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), clinical trials registries, and OpenGrey from inception to April 2020 according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Studies of patients undergoing free tissue transfer reconstruction for chronic venous ulcers in the lower limb were included.
A total of 5 noncomparative cohort studies featuring 56 patients with 62 recalcitrant venous ulcers treated with 64 free flaps who had a mean age of 50 years (range, 17-76 years) were included, and a narrative analysis undertaken. Mean defect size following ulcer debridement was 153.3 cm 2 (range, 24-600 cm 2 ). Defects were reconstructed with muscle (n = 39 [60.9%]), fasciocutaneous (n = 23 [35.9%]), and visceral (n = 2 [3.1%]) free flaps, with latissimus dorsi (n = 16, 25%) and rectus abdominis flaps (n = 16, 25%) being the most frequently used. Mean follow-up ranged from 24 to 125 months. Pooled flap survival rate was 95%. No recurrence within the territory of the flap was reported, but there were 20 instances (35.7%) of new ulcers outside of the flap boundaries.
There is currently an absence of evidence to support the use of free flap reconstruction for recalcitrant venous ulcers compared with conventional management. Although evidence suggests that it is technically feasible, there is no evidence to suggest it prevents ulceration outside the reconstructed region. Further studies are necessary to evaluate its effectiveness for venous ulcers in the lower limb.
静脉溃疡的主要治疗方法是保守的伤口管理和终身压迫治疗。对于顽固的溃疡患者,游离皮瓣重建已被提议作为一种治疗选择,以重建患病的软组织以及潜在的静脉系统不足。本综述系统评估了游离皮瓣重建治疗下肢慢性静脉溃疡的结果。
事先制定了方案,并在 PROSPERO 数据库中进行了注册。根据 PRISMA(系统评价和荟萃分析的首选报告项目)指南,从开始到 2020 年 4 月,在 MEDLINE、EMBASE、Cochrane 中央对照试验注册中心(CENTRAL)、临床试验登记处和 OpenGrey 中对文献进行了系统搜索,纳入了接受游离组织转移重建治疗下肢慢性静脉溃疡的患者。
共纳入 5 项非对照队列研究,共纳入 56 例 62 例难治性静脉溃疡患者,64 例游离皮瓣,平均年龄 50 岁(范围 17-76 岁),进行了叙述性分析。溃疡清创后平均缺损大小为 153.3cm 2 (范围 24-600cm 2 )。缺损采用肌肉(n=39[60.9%])、筋膜皮瓣(n=23[35.9%])和内脏(n=2[3.1%])游离皮瓣重建,其中背阔肌皮瓣(n=16,25%)和腹直肌皮瓣(n=16,25%)最常使用。平均随访时间从 24 到 125 个月不等。皮瓣存活率为 95%。报告的皮瓣区域内无复发,但有 20 例(35.7%)新溃疡位于皮瓣边界外。
目前尚无证据支持游离皮瓣重建治疗难治性静脉溃疡与传统治疗相比的优越性。尽管证据表明该方法在技术上是可行的,但没有证据表明它可以防止重建区域外的溃疡形成。需要进一步的研究来评估其在下肢静脉溃疡中的有效性。